Strasbourg, France, May 25, 2016 – Transgene (Euronext Paris: TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the new composition of its board of directors and the appointment of new statutory auditors following yesterday’s annual shareholders’ meeting (AGM).
The AGM appointed Mr Antoine Béret as an independent director, to replace Mr Arnaud Fayet who did not seek a renewal of his term.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.65 (c)||1.92%||62 761|